Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GC33 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| GC33 (RO5137382) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | iv Days 1 and 8, and every 2 weeks thereafter |
| GC33 | DRUG | 1600 mg iv Day 1 and 8, and every 2 weeks thereafter |
Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically confirmed hepatocellular carcinoma (without fibro-lamellar subtype) * Prior treatment with at least 1 systemic agent, with documented progressive disease after systemic agent(s), or documented adverse event(s) associated wi...
GC33 is an investigational drug being studied for the treatment of advanced or metastatic hepatocellular carcinoma, a type of liver cancer. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being developed by Roche Holding AG.
GC33 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded over-the-counter under the ticker symbol RHHBY. The drug is currently in Phase 2 clinical trials for hepatocellular carcinoma.
GC33 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. A Phase 2 study of GC33 in patients with advanced or metastatic hepatocellular carcinoma has been completed.
GC33 has been studied in one clinical trial, identified as NCT01507168. This was a Phase 2, randomized, double-blind, placebo-controlled study in patients with advanced or metastatic hepatocellular carcinoma. The trial enrolled 185 participants and has been completed.
Yes, GC33 is also known as RO5137382. In clinical trial NCT01507168, the drug is referred to as GC33 (RO5137382). This alternative name may be used in scientific literature and regulatory documents.